Canada's consent-driven data silos and the U.S.'s regulatory patchwork aren't just administrative hurdles — they're determinants of bias in real-world evidence.
Implementing Regulation (EU) 2025/1466 is in full effect — and it's the biggest change to EU pharmacovigilance rules in over a decade. Here's what your compliance team needs to act on right now.
UBC joined patients, researchers, and industry leaders at this year’s Rare Disease Day at NIH to discuss advancing research, improving diagnostics, and accelerating treatments for those living with rare diseases.
Bekki Bracken Brown serves as the President and CEO of UBC, guiding the company’s mission and values, including the improvement of access for patients to receive better outcomes. She oversees all aspects of UBC, such as operations, business growth strategy, sales and marketing, and acquisition support.
With over 20 years of industry experience, Ms. Brown brings knowledge from a successful career in senior management from her tenure at Quintiles, INC Research, and, most recently, with Syneos Health. She’s been a member of the North Carolina BIO Board of Directors since 2019. She is also a member of the Healthcare Businesswomen’s Association — Southeast Chapter and CHIEF, an organization that supports women executive leaders. Ms. Brown earned her bachelor’s degree at Duke University.